<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128358</url>
  </required_header>
  <id_info>
    <org_study_id>Skhaled21</org_study_id>
    <nct_id>NCT04128358</nct_id>
  </id_info>
  <brief_title>Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?</brief_title>
  <official_title>Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic thrombocytopenic purpura (ITP) is a benign hematological disorder characterized by
      isolated thrombocytopenia. Development of antiplatelet autoantibodies is the main
      pathogenetic mechanism in patients with ITP. However the exact pathogenesis of ITP is complex
      in which megakaryocyte immune injury and T-cell mediated platelet destruction play
      significant role. Accordingly treatment of ITP relies mainly on immunosuppression. Recently
      triple regimen of high dose dexamethasone together with cyclosporine and rituximab was found
      to induce prolonged remission in patients with ITP compared with single agent
      immunosuppression. On the other hand this regimen suppresses all immune cells thus
      predisposing patient to serious infections, which is the main cause of morbidity in ITP
      furthermore infection enhances autoimmunity.

      This study will focus on viral hepatitis C and B infection in Egyptian patients with
      idiopathic thrombocytopenic purpura on Triple therapy and aims to:

        -  Assess and improve preventive measures of blood born hepatitis infection in the
           hematology ward in Egypt.

        -  Investigate influence of immunosuppression on infection with blood born hepatitis on
           Egyptian patients with ITP on Triple therapy.

        -  Study the impact of blood born hepatitis infection on clinical outcome on those
           patients.

        -  Identify risk factors and routes of transmission of blood born viral hepatitis in the
           hematology ward in Egypt
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood born viral hepatitis is a type of viral hepatitis that is usually transmitted with
      transfusion of blood and blood products. Accordingly patients with hematological disorders
      are at higher risk for infection with blood born hepatitis as blood transfusion besides
      regular sampling are integral parts in management of hematological patients. This was the
      case in patients with ITP, however not all patients with ITP in need for regular platelet
      transfusion. The mainstay of treatment of ITP is immunosuppression, that was mainly dependent
      on parenteral or oral steroids for long time. Triple therapy was recently introduced for
      treatment of patients with ITP it induces strong immunosuppression that could make patients
      vulnerable to infections.

      Several studies accused immunosuppression in patients with hematological malignancies under
      chemotherapy to be a risk factor for infection with blood born hepatitis, as such triple
      therapy could predispose patients with ITP to blood born viral hepatitis infection.

      On the other hand infection with blood born hepatitis in patients with ITP on Triple therapy
      could affect patient outcome and response to treatment. This is because thrombocytopenia is a
      common extra hepatic manifestation of hepatitis C viral infection on its chronic form.

      Egypt is a country with high prevalence of blood born viral hepatitis viral hepatitis C.
      Recently, the president of Egypt elaborated an initiative (100 million Health) that was
      managed with the Ministry of Health in all over the country. This initiative aimed to
      eliminate blood born hepatitis particularly C from the Country.

      This work will be conducted in Egypt and focused on ITP patients on Triple therapy to assess
      their vulnerability for infection with blood born hepatitis as they are a particular sector
      of the Egyptian population at higher risk for infection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized clinical trial aimed to assess the effect of strong immunosuppression in patients with ITP on Triple therapy on acquiring viral hepatitis infection C or B.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence</measure>
    <time_frame>6-months</time_frame>
    <description>Number of ITP patients on Triple therapy became infected with blood born viral hepatitis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet count</measure>
    <time_frame>6-months</time_frame>
    <description>Number of ITP patients on Triple therapy infected with HCV or HBV and their platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary prevention</measure>
    <time_frame>One month</time_frame>
    <description>Number of medical and paramedical staff who follow preventive measures for HCV and HBV in the hematology ward before and after an educational program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factors</measure>
    <time_frame>6-months</time_frame>
    <description>Number of ITP patients who became infected with HCV or HBV after exposure to a risk factor</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Group on high dose dexamethasone, cyclosporin and rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Egyptian patients with idiopathic thrombocytopenic purpura on high dose dexamethasone together with cyclosporine and rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group on steroids only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Egyptian patients with idiopathic thrombocytopenic purpura on parenteral or oral steroids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Egyptian normal healthy volunteers who share on the President Initiative (100 Million Health).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serological assay for blood born viral hepatitis</intervention_name>
    <description>Qualitative PCR for patients with hepatitis C antibody positive</description>
    <arm_group_label>Group on high dose dexamethasone, cyclosporin and rituximab</arm_group_label>
    <arm_group_label>Group on steroids only</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Qualitative Polymerase chain reaction (PCR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative microbiological test for HCV</intervention_name>
    <description>Quantitative PCR in those with proven HCV infection</description>
    <arm_group_label>Group on high dose dexamethasone, cyclosporin and rituximab</arm_group_label>
    <arm_group_label>Group on steroids only</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal healthy Egyptians on the age range from 18-85.

          -  Egyptian patients with ITP in age range from 18- 65 on high dose dexamethasone
             together with cyclosporin and rituximab .

          -  Egyptian patients with ITP in age range from 18- 65 on parenteral or oral steriods.

        Exclusion Criteria:

          -  Age less than 18 years old.

          -  Pregnancy

          -  Thrombocytopenia other than ITP.

          -  Patients with ITP but on other modalities of treatment.

          -  Patients with blood born viral hepatitis infection before treatment with high dose
             dexamethasone together with cyclosporin and rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed El yamany, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shymaa M Nageeb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman NaserEldin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Khair, Ass. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Safaa A Khaled, Ass. Prof.</last_name>
    <phone>01064170058</phone>
    <phone_ext>002</phone_ext>
    <email>safaakhaled2003@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohamed El Menshawy, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.</citation>
    <PMID>19005182</PMID>
  </reference>
  <reference>
    <citation>Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol. 2005 Feb;81(2):106-12. Review.</citation>
    <PMID>15765777</PMID>
  </reference>
  <reference>
    <citation>Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012 Jun 21;119(25):5989-95. doi: 10.1182/blood-2011-11-393975. Epub 2012 May 7.</citation>
    <PMID>22566601</PMID>
  </reference>
  <reference>
    <citation>Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Rønnov-Jessen D, Hasselbalch HC. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013 Mar 14;121(11):1976-81. doi: 10.1182/blood-2012-09-455691. Epub 2013 Jan 4.</citation>
    <PMID>23293082</PMID>
  </reference>
  <reference>
    <citation>Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16. Review.</citation>
    <PMID>28404132</PMID>
  </reference>
  <reference>
    <citation>Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018 Jan 26;8(1):1661. doi: 10.1038/s41598-017-17936-4. Review.</citation>
    <PMID>29374178</PMID>
  </reference>
  <reference>
    <citation>Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.</citation>
    <PMID>24713006</PMID>
  </reference>
  <reference>
    <citation>Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis. 2004 Sep 15;39(6):790-6. Epub 2004 Aug 27.</citation>
    <PMID>15472809</PMID>
  </reference>
  <reference>
    <citation>Aref S, Sleem T, El Menshawy N, Ebrahiem L, Abdella D, Fouda M, Samara NA, Menessy A, Abdel-Ghaffar H, Bassam A, Abdel Wahaab M. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematology. 2009 Oct;14(5):277-81. doi: 10.1179/102453309X439818.</citation>
    <PMID>19843383</PMID>
  </reference>
  <reference>
    <citation>Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, Tanimoto M, Hatake K. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol. 2008 Jan;83(1):59-62.</citation>
    <PMID>17712791</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 13, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Safaa AA Khaled</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

